VORN Bioenergy announces appointments to leadership team
Regensburg. VORN Bioenergy today announces the appointment of Jörg Lennertz as Chief Executive Officer and Manuel Fernández Durán as Chief Financial Officer. Jörg and Manuel together with Michael Wallis Olausson form the new management team.
Jörg Lennertz is an experienced leader in the bioenergy sector. Joining VORN Bioenergy from Uniper, he played a key role in building the company’s multi-gigawatt European renewable energy business. Jörg’s experience, from project development through to execution as well as in scaling up, will be valuable for implementing VORN Bioenergy’s ambitious growth strategy across Germany, Italy, the Iberian Peninsula and Poland. Jörg Lennertz succeeds Thorsten Holl who over the past three years, restructured the company, repositioned it, and established its foundations for growth.
Jörg Lennertz says: “VORN Bioenergy has decades of experience in realizing and commercially optimizing biomethane assets, and I’m delighted to join them as they enter a new phase of execution, providing sizeable feedstock and offtake opportunities across Europe. I’m looking forward to continuing this momentum as we aim to be the partner of choice for current and future feedstock suppliers and offtakers, and continue to support Europe’s decarbonisation.”
Manuel Fernández brings over 18 years of CFO experience, recently at BlueFloat Energy. He brings deep knowledge in project financing and proven ability to build and scale finance teams for long-term growth.
The management team at VORN Bioenergy is completed by Michael Wallis Olausson, who joined as Chief Operating Officer (COO) in February 2025 brings deep expertise from over 15 years biogas industry experience, particularly on project construction and operation.
Chris Archer, Head of Macquarie Asset Management, Green Investments EMEA, the shareholder of VORN Bioenergy, says: “We would like to express our sincere thanks to Thorsten Holl and Dirk Simons for their leadership and dedication in recent years. As we look to the future, the complementary strengths Jörg, Manuel and Michael bring position VORN exceptionally well to deliver on its growth ambitions.”
The VORN Bioenergy Group is an innovative developer, deliverer and operator of biomethane plants in Europe. The company, which has been independent since 2022, can look back on more than 20 years of project experience and has realised more than 40 bioenergy projects in Europe. The company is based in Regensburg, Germany, and its operational focus is on Germany, Italy, Spain and Poland. VORN Bioenergy pursues the consistent goal of operating emission-free and producing two TWh of biomethane per year by 2030.
Contacts
Wilfried.Sauer.extern@vornbioenergy.com
Phone: +49174 49 60 605
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
INTERSPORT Austria acquires INTERSPORT Slovenia Group15.1.2026 14:11:33 CET | Press Release
Strategic move strengthens market position in Central Europe, with over 500 locations in 12 countries and more than € 1 billion in sales
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 12:34:15 CET | Press Release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner13.1.2026 09:00:00 CET | Press Release
Zoetermeer, Netherlands - 13 January 2026 - Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
ESSL leading study to find where and why damaging hail is getting worse12.1.2026 13:38:03 CET | Press Release
Wiener Neustadt, Austria jan 12, 2026 - First comprehensive global study of very large hail in a changing climate reveals contrasting trends and different causes.
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press Release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom